Bayer Aktiengesellschaft (LON:0P6S)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 34.17B +103.6% |
| Revenue (ttm) | 39.76B -2.2% |
| Net Income | -3.16B |
| EPS | -3.21 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 9.42 |
| Dividend | 0.09 (0.23%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 535,551 |
| Average Volume | 891,219 |
| Open | 41.69 |
| Previous Close | 41.19 |
| Day's Range | 39.94 - 41.78 |
| 52-Week Range | 21.17 - 49.78 |
| Beta | 0.89 |
| RSI | 54.27 |
| Earnings Date | May 12, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
The Cancer Victims Who Could Sink Bayer's Roundup Settlement
With thousands of cases piling up in U.S. courts, the company's relief plans still face hurdles.
US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims
A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer in hal...
U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims
A federal judge rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer i...
Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new sc...
Bayer US head says tariffs will not affect its 2026 forecasts
A top Bayer AG executive said on Tuesday the German drugmaking and crop science company saw no need to adjust its 2026 forecasts because of tariffs on imported pharmaceuticals announced by the U.S. ...
National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men's Pre-Conception Health Complete Multivitamin Claims
Following a challenge brought by OLLY PBC, BBB National Programs' National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify certain claims for its One A Day® Men's Pre-...
Bayer Announces Leadership Change Within Pharmaceuticals' Worldwide Markets Organization in the U.S. to Support Company's Full Growth Potential
BERLIN--(BUSINESS WIRE)--Bayer today announced a leadership change within its Pharmaceuticals' Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical ...
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to challenge and redefine how it thinks about canola innovation in sup...
Activist investor Inclusive Capital looks to sell stake in Bayer, Bloomberg News reports
Inclusive Capital Partners is looking to sell a stake in German agriculture and health firm Bayer AG , Bloomberg News reported on Monday.
Bayer Crop Science Launches 2026 Opportunity Scholarship Program
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship,...
Bayer takes its multi-front battle on pesticide liability to Kansas
Kansas lawmakers were set to take up a bill on Tuesday backed by Bayer that would prevent people from suing pesticide manufacturers for not warning them that their products could cause cancer or othe...
Bayer's $7.25 billion Roundup settlement gets initial OK from Missouri judge
A state court judge in Missouri gave an initial green light on Wednesday to a proposed $7.25 billion settlement to resolve thousands of lawsuits claiming Bayer's Roundup weedkiller causes cancer.
New FDA 510(k) Clearance Expands Bayer's MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (...
Bayer Net Loss Widens on Weedkiller Litigation Charges
The agriculture and pharmaceutical company reported a steeper net loss, including a €3.55 billion hit mainly from litigation-related expenses.
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ef...
Bayer's XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases.
Some roundup plaintiffs seek to delay preliminary approval of proposed $7.25 bln bayer settlement, court filing shows
Law firms representing nearly 20,000 people who sued Bayer over alleged injuries from its Roundup weedkiller urged a Missouri judge on Wednesday to delay reviewing the German company's proposed $7.25 ...
Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of...
Bayer, John Deere Further Integrate FieldView and Operations Center to Improve Customer Experience for 2026 Season
ST. LOUIS--(BUSINESS WIRE)--Bayer and John Deere today announced a new capability that simplifies how U.S. farmers and advisors move from agronomic decisions to precise execution in the field. Beginni...
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-grade ...
Bayer proposes $7.25 billion Roundup settlement as Supreme Court case looms
A new $7.25 billion settlement between Bayer and a group of cancer patients could wrap up a huge wave of lawsuits against the company over allegations that it didn't warn consumers about cancer risks ...
Bayer: glyphosate shortages not expected outside the US after executive order
The U.S. President's executive order invoking the Defense Production Act to ensure U.S. supply of glyphosate underscores U.S. farmers' needs to have access to the herbicide, Bayer said on Thursday, ad...
Explainer: Will Bayer's proposed $7.25 billion Roundup deal bring legal closure?
Bayer's Monsanto unit has proposed a $7.25 billion nationwide class settlement to resolve both current and future lawsuits alleging that its Roundup weedkiller caused cancer, billing it as a long-awai...
Bayer retreats as investors sour on deal to settle Roundup litigation
Bayer's shares slumped as much as 9.2% on Wednesday, wiping out the previous day's gains, as investors questioned whether a proposed $7.25 billion settlement of cancer lawsuits over its Roundup weedki...